Tumor-suppressing gene therapy
- PMID: 14508088
Tumor-suppressing gene therapy
Abstract
Tumor-suppressor genes play pivotal roles in maintaining genome integrity and in regulating cell proliferation, differentiation, and apoptosis. Their loss-of-function mutations are related directly to tumorigenesis. Thus, use of tumor-suppressor genes as anticancer therapeutics has been investigated rigorously in both experimental and clinical researches. Transfer of various tumor-suppressor genes directly to cancer cells has been demonstrated to suppress tumor growth via induction of apoptosis and cell-cycle arrest and, in some cases, with evidence for bystander effects. Various studies also have shown that combination of tumor-suppressor gene therapy with conventional anticancer therapy can yield synergistic therapeutic benefits. Clinical trials with tumor-suppressor genes, especially the p53 gene, have demonstrated that the treatment is well tolerated, and; favorable clinical responses, including a pathologically complete responses, have been observed in a subset of patients with advanced disease or with cancers resistant to conventional therapy. Yet, current gene replacement approaches in cancer gene therapy must be improved if they are to have a broader clinical impact. Efficient systemic gene delivery systems will be required ultimately for treatment of metastatic disease. In this review, we have recently summarized achievements in tumor-suppressor gene therapy with a focus on the p53 gene.
Similar articles
-
INGN 201: Ad-p53, Ad5CMV-p53, adenoviral p53, p53 gene therapy--introgen, RPR/INGN 201.Drugs R D. 2007;8(3):176-87. doi: 10.2165/00126839-200708030-00005. Drugs R D. 2007. PMID: 17472413 Review.
-
Gene therapy approaches for the management of non-small cell lung cancer.Semin Oncol. 2001 Aug;28(4 Suppl 14):50-6. doi: 10.1016/s0093-7754(01)90060-0. Semin Oncol. 2001. PMID: 11605184 Review.
-
INGN 201: Ad-p53, Ad5CMV-p53, Adenoviral p53, INGN 101, p53 gene therapy--Introgen, RPR/INGN 201.BioDrugs. 2003;17(3):216-22. doi: 10.2165/00063030-200317030-00010. BioDrugs. 2003. PMID: 12749760 Review.
-
p53 tumor suppressor gene therapy for cancer.Oncology (Williston Park). 1999 Oct;13(10 Suppl 5):148-54. Oncology (Williston Park). 1999. PMID: 10550840 Review.
-
Advances in adenovirus-mediated p53 cancer gene therapy.Expert Opin Biol Ther. 2013 Nov;13(11):1569-83. doi: 10.1517/14712598.2013.845662. Expert Opin Biol Ther. 2013. PMID: 24107178
Cited by
-
von Willebrand factor type D domain mutant of SVS-1/SUSD2, vWD(m), induces apoptosis in HeLa cells.Cancer Sci. 2007 Jun;98(6):909-15. doi: 10.1111/j.1349-7006.2007.00467.x. Epub 2007 Apr 12. Cancer Sci. 2007. PMID: 17428257 Free PMC article.
-
Gene therapy of liver cancer.World J Gastroenterol. 2006 Oct 14;12(38):6085-97. doi: 10.3748/wjg.v12.i38.6085. World J Gastroenterol. 2006. PMID: 17036377 Free PMC article. Review.
-
An Overview: Genetic Tumor Markers for Early Detection and Current Gene Therapy Strategies.Cancer Inform. 2023 Feb 1;22:11769351221150772. doi: 10.1177/11769351221150772. eCollection 2023. Cancer Inform. 2023. PMID: 36762284 Free PMC article. Review.
-
Not gene therapy, but genetic surgery-the right strategy to attack cancer.Mol Gen Microbiol Virol. 2009;24(3):93-113. doi: 10.3103/S089141680903001X. Epub 2009 Oct 8. Mol Gen Microbiol Virol. 2009. PMID: 32214647 Free PMC article.
-
Awakening guardian angels: drugging the p53 pathway.Nat Rev Cancer. 2009 Dec;9(12):862-73. doi: 10.1038/nrc2763. Nat Rev Cancer. 2009. PMID: 19935675 Review.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Medical
Research Materials
Miscellaneous